Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Sarcoma 1Rhabdomyosarcoma 1Neurofibromatosis 2 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Medulloblastoma 1Hemangiosarcoma 1Colorectal Neoplasms 1Cholangiocarcinoma 1

Interventions

Oxaliplatin 270Bevacizumab 260Fluorouracil 249Irinotecan 240Leucovorin 218Capecitabine 196Cetuximab 161Colonoscopy 74Folfox protocol 70Panitumumab 64regorafenib 62Drug Therapy 52Radiotherapy 50HMPL-013 50Blood Specimen Collection 45trifluridine tipiracil drug combination 43pembrolizumab 41Surveys and Questionnaires 35Standard of Care 35Nivolumab 34Neoadjuvant Therapy 34Surgical Procedures, Operative 33Magnetic Resonance Spectroscopy 31IFL protocol 27Trifluridine 26Interviews as Topic 26Celecoxib 26XELOX 25Early Intervention, Educational 24Specimen Handling 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Colorectal Neoplasms × Vascular Endothelial Growth Factor A × Clear all
NCT00483834 2019-02-15

A Phase II Study of Bevacizumab, Irinotecan and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer

University Health Network, Toronto

Phase 2 Completed
50 enrolled
Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡